Evidence map›Paper›PMID 39660665›Full record

ArticleClinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery2025

'How Long Do I Have?' - Examining survival outcomes in laryngeal cancer patients managed with non-curative intent in Northern UK: Insights from the Northern Head & Neck Cancer Alliance Retrospective Study.

Amarkumar Rajgor, Rhona Hurley, Catriona M Douglas, Claire Paterson, James Moor, Shane Lester, Sara Sionis, Katharine Davies, James O'Hara, Gareth Inman and 3 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amarkumar RajgorNational Institute for Health & Care Research Doctoral Fellow in Otolaryngology, Population Health Sciences Institute, Newcastle University, Newcastle-Upon-Tyne, UK.
Rhona HurleyNHS Greater Glasgow & Clyde, Newcastle-Upon-Tyne, UK.ORCID 0000-0003-3632-7606
Catriona M DouglasNHS Greater Glasgow & Clyde, Newcastle-Upon-Tyne, UK.
Claire PatersonNHS Greater Glasgow & Clyde, Newcastle-Upon-Tyne, UK.ORCID 0000-0002-1691-5016
James MoorLeeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.ORCID 0000-0002-4399-0572
Shane LesterSouth Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
Sara SionisSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Katharine DaviesLiverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
James O'HaraNewcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle-Upon-Tyne, UK.
Gareth InmanNHS Greater Glasgow & Clyde, Newcastle-Upon-Tyne, UK.
Terry JonesLiverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
David Winston HamiltonNewcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle-Upon-Tyne, UK.
Northern Head & Neck Alliance

Funding

National Institute for Health and Care Research NIHR302984
6 · The paper itself

Abstract

introductionHistorically, 15% of laryngeal cancer patients undergo non-curative management, but pragmatic data on this group are limited. This information is crucial to help patients make informed decisions about their care. Supported by the Northern Head & Neck Alliance, this retrospective study is the first to present survival outcomes for non-curative laryngeal cancer patients in Northern UK.

methodsRetrospective data were compiled for patients with laryngeal squamous cell cancer from five large tertiary head and neck centres in Northern UK (Newcastle, Glasgow, Sheffield, Leeds, and Middlesbrough). The collected data encompassed demographic details, treatment and clinical outcomes.

resultsAmong 373 patients, the mean age was 72, and 73% were male. The median follow-up was 6 months. 17% had early-stage (T1-2), and 83% had late-stage (T3-4) disease. By data collection, 99% had died. The mean survival time (MST) was 9.1 months. Patients with metastases had an MST of 6.9 months, while those without had 9.4 months. Early-stage patients had an MST of 13.3 months, compared to 8.2 months for advanced disease. By subsite, MSTs were 8.2 months for supraglottic, 12.5 for glottic, 5.5 for subglottic, and 7.9 for transglottic cancers.

conclusionThis study stands as the first to explore survival outcomes in laryngeal cancer patients undergoing non-curative management. The findings can provide valuable insights for informing patients about survival in the absence of radical treatment, facilitating important decision-making conversations.

Indexed as

Carcinoma, Squamous CellLaryngeal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesSurvival RateUnited KingdomLaryngeal cancerMultidisciplinary approachPalliative careSurvival outcomes

Identifiers

PMID39660665
PMCPMC11792425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.